IDH3A and neoplasm: It has been used to grade tumours, evaluate response to therapy and predict genetic status of GBM—for example, isocitrate dehydrogenase (IDH) status in GBM, which is of clinical significance since negative status (or ‘wildtype’) implies a more aggressive tumour [33].